Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Manfred Schmitt; Karin Mengele; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Apostolos Gkazepis; Fred Sweep; Nils Brunner; John Foekens; Nadia Harbeck

doi:10.1586/erm.10.71

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Manfred Schmitt, Karin Mengele, Rudolf Napieralski, Viktor Magdolen, Ute Reuning, Apostolos Gkazepis, Fred Sweep, Nils Brunner, John Foekens, Nadia Harbeck

55 Citations (Scopus)

Abstract

The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.

Original language	English
Journal	Expert Review of Molecular Diagnostics
Volume	10
Issue number	8
Pages (from-to)	1051-1067
Number of pages	17
ISSN	1473-7159
DOIs	https://doi.org/10.1586/erm.10.71
Publication status	Published - Nov 2010

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1586/erm.10.71

Cite this

@article{a5658ee1c0774e85bb699dd62df9343a,

title = "Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1",

abstract = "The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.",

author = "Manfred Schmitt and Karin Mengele and Rudolf Napieralski and Viktor Magdolen and Ute Reuning and Apostolos Gkazepis and Fred Sweep and Nils Brunner and John Foekens and Nadia Harbeck",

year = "2010",

month = nov,

doi = "10.1586/erm.10.71",

language = "English",

volume = "10",

pages = "1051--1067",

journal = "Expert Review of Molecular Diagnostics",

issn = "1473-7159",

publisher = "Taylor & Francis",

number = "8",

}

TY - JOUR

T1 - Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

AU - Schmitt, Manfred

AU - Mengele, Karin

AU - Napieralski, Rudolf

AU - Magdolen, Viktor

AU - Reuning, Ute

AU - Gkazepis, Apostolos

AU - Sweep, Fred

AU - Brunner, Nils

AU - Foekens, John

AU - Harbeck, Nadia

PY - 2010/11

Y1 - 2010/11

N2 - The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.

AB - The prognostic and/or predictive value of the cancer biomarkers, urokinase-type plasminogen activator (uPA) and its inhibitor (plasminogen activator inhibitor [PAI]-1), determined by ELISA in tumor-tissue extracts, was demonstrated for several cancer types in numerous clinically relevant retrospective or prospective studies, including a multicenter breast cancer therapy trial (Chemo-N0). Consequently, for the first time ever for any cancer biomarker for breast cancer, uPA and PAI-1 have reached the highest level of evidence, level-of-evidence-1. At present, two other breast cancer therapy trials, NNBC-3 and Plan B, also incorporating uPA and PAI-1 as treatment-assignment tools are in effect. Furthermore, small synthetic molecules targeting uPA are currently in Phase II clinical trials in patients afflicted with advanced cancer of the ovary, breast or pancreas.

U2 - 10.1586/erm.10.71

DO - 10.1586/erm.10.71

M3 - Journal article

SN - 1473-7159

VL - 10

SP - 1051

EP - 1067

JO - Expert Review of Molecular Diagnostics

JF - Expert Review of Molecular Diagnostics

IS - 8

ER -

Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this